| Aryna Sabalenka beats Jessica Pegula to win the US Open for her third Grand Slam title |
AP Online |
09/07 |
21:20 |
| US Open: Jessica Pegula reaches her first Grand Slam final at age 30 and will play Aryna Sabalenka |
AP Online |
09/06 |
00:24 |
| NFL Taps TuneIn to Host International Audio Coverage for the 2024 Season |
Globe Newswire |
09/05 |
10:01 |
| DraftKings Announces Jason Robins’ Participation in Upcoming Event |
Globe Newswire |
09/04 |
16:30 |
| Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma) |
Globe Newswire |
09/03 |
08:30 |
| Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML |
Globe Newswire |
09/03 |
08:00 |
| Big 12 Conference and TuneIn Launch ‘Big 12 Radio’ to Bring College Sports Fans Non-Stop Conference Coverage |
Globe Newswire |
08/27 |
09:00 |
| Sportradar Announces Upcoming Investor Conference Participation Schedule |
Globe Newswire |
08/27 |
08:00 |
| Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024 |
Globe Newswire |
08/27 |
07:00 |
| Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma |
Globe Newswire |
08/26 |
07:00 |
| TuneIn Ramps Up Division 1 College Football Coverage for the 2024-2025 Season |
Globe Newswire |
08/23 |
14:04 |
| Jet.AI Announces Entry Into Warrant Amendments After Successful Warrant Exchange Offer and Consent Solicitation |
Globe Newswire |
08/23 |
08:05 |
| Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma |
Globe Newswire |
08/23 |
01:00 |
| Catapult Launches Live In Game Video Solutions with the SEC |
Globe Newswire |
08/20 |
07:00 |
| TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma |
Globe Newswire |
08/19 |
14:00 |
| Mantle Cell Lymphoma Treatment Market is Projected to Reach US$ 5.77 Billion by 2034, with a 8.6% CAGR | Fact.MR Report |
Globe Newswire |
08/15 |
10:30 |
| Jet.AI Reports Second Quarter 2024 Financial Results |
Globe Newswire |
08/14 |
21:35 |
| Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates |
Globe Newswire |
08/14 |
20:30 |
| Enthusiast Gaming Reports Q2 2024 Results |
Globe Newswire |
08/14 |
20:10 |
| Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights |
Globe Newswire |
08/14 |
01:03 |
| Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights |
Globe Newswire |
08/13 |
20:01 |
| Sportradar Reports Second Quarter 2024 Financial and Operating Results |
Globe Newswire |
08/13 |
11:00 |
| Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update |
Globe Newswire |
08/13 |
10:40 |
| Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma |
Globe Newswire |
08/12 |
11:00 |
| ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
Globe Newswire |
08/08 |
20:05 |
